ArticleSignal transduction and targeted therapy2023

Discovery of C19-9 as a novel non-RGD inhibitor of αvβ3 to overcome enzalutamide resistance in castration-resistant prostate cancer.

Xiaocong Pang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.